Journal of Biological Chemistry · 1995 · 47 citations · 40 references
MedicineHematologyImmunologyHemostasisMolecular ImmunologyMonoclonal AntibodiesPlatelet ActivationPlatelet AdhesionPlatelet AggregationPlatelet FunctionPlatelet PhysiologyThrombosisPlatelet Adhesion MoleculesPlatelet Function ModulationPlatelet Receptor SignalingPlatelet Surface Receptors
NNKY 1-19, anti-CD9 monoclonal antibody (MoAb), induced protein tyrosine phosphorylation of 125-, 97-, 75-, 64-, and 40-kDa proteins in human platelets, whereas F(ab′)2 fragments of NNKY 1-19 did not, suggesting that the stimulation of FcγII receptors is required for the induction of protein tyrosine phosphorylation. Tyrosine-phosphorylated proteins of 97 and 125 kDa were associated with aggregation, while NNKY 1-19-induced protein tyrosine phosphorylation was completely inhibited by prostaglandin I2 (PGI2). The activity of p72syk was assessed in immunoprecipitation kinase assays to determine at which step the signal transduction pathway leading to protein tyrosine phosphorylation was suspended. NNKY 1-19 induced a rapid and transient increase in the p72syk-associated tyrosine kinase activity that peaked at 10 s and subsided to the original level 2 min after stimulation. Coinciding with this time course, p60c-src transiently associated with p72syk. In platelets preexposed to GRGDS peptides or PGI2, NNKY 1-19 also increased the p72syk-associated tyrosine kinase activity and led to the association of p60c-src with p72syk. However, in contrast to the control without any inhibitor, the elevated tyrosine kinase activity and the associated state of the two tyrosine kinases persisted as long as 5 min after stimulation. F(ab′)2 fragments of NNKY 1-19 induced changes similar to those observed with the effects of GRGDS peptides or PGI2 treatment on intact IgG NNKY 1-19 stimulation. F(ab′)2 fragments of another CD9 MoAb, PMA2, had effects on p72sykessentially similar to those of NNKY 1-19. These findings suggest that the binding of anti-CD9 MoAb to CD9 on the platelet membrane per se induces an increase in the p72syk-associated tyrosine kinase activity but that FcγII receptor-mediated signal(s) is required for the full activation of platelets and the appearance of tyrosine-phosphorylated proteins. The elevated intracellular cAMP level induced by PGI2 acts at a step distal to the activation of p72syk and inhibited the signal transduction pathway leading to protein tyrosine phosphorylation and aggregation. p72sykactivation occurs in the absence of aggregation, but aggregation appears to reduce the elevated p72syk activity induced by anti-CD9 MoAb. NNKY 1-19, anti-CD9 monoclonal antibody (MoAb), induced protein tyrosine phosphorylation of 125-, 97-, 75-, 64-, and 40-kDa proteins in human platelets, whereas F(ab′)2 fragments of NNKY 1-19 did not, suggesting that the stimulation of FcγII receptors is required for the induction of protein tyrosine phosphorylation. Tyrosine-phosphorylated proteins of 97 and 125 kDa were associated with aggregation, while NNKY 1-19-induced protein tyrosine phosphorylation was completely inhibited by prostaglandin I2 (PGI2). The activity of p72syk was assessed in immunoprecipitation kinase assays to determine at which step the signal transduction pathway leading to protein tyrosine phosphorylation was suspended. NNKY 1-19 induced a rapid and transient increase in the p72syk-associated tyrosine kinase activity that peaked at 10 s and subsided to the original level 2 min after stimulation. Coinciding with this time course, p60c-src transiently associated with p72syk. In platelets preexposed to GRGDS peptides or PGI2, NNKY 1-19 also increased the p72syk-associated tyrosine kinase activity and led to the association of p60c-src with p72syk. However, in contrast to the control without any inhibitor, the elevated tyrosine kinase activity and the associated state of the two tyrosine kinases persisted as long as 5 min after stimulation. F(ab′)2 fragments of NNKY 1-19 induced changes similar to those observed with the effects of GRGDS peptides or PGI2 treatment on intact IgG NNKY 1-19 stimulation. F(ab′)2 fragments of another CD9 MoAb, PMA2, had effects on p72sykessentially similar to those of NNKY 1-19. These findings suggest that the binding of anti-CD9 MoAb to CD9 on the platelet membrane per se induces an increase in the p72syk-associated tyrosine kinase activity but that FcγII receptor-mediated signal(s) is required for the full activation of platelets and the appearance of tyrosine-phosphorylated proteins. The elevated intracellular cAMP level induced by PGI2 acts at a step distal to the activation of p72syk and inhibited the signal transduction pathway leading to protein tyrosine phosphorylation and aggregation. p72sykactivation occurs in the absence of aggregation, but aggregation appears to reduce the elevated p72syk activity induced by anti-CD9 MoAb. INTRODUCTIONA number of antibodies directed against antigens on the platelet membrane activate platelets (Horsewood et al., 1991). Whereas the antigens involved are diverse, the known antibodies with stimulatory properties are predominantly against CD9, a 24-kDa cell surface glycoprotein (Higashihara et al., 1985; Rendu et al., 1987; Jennings et al., 1990; Carroll et al., 1990), which is confirmed by the fact that most of the monoclonal antibodies (MoAbs)1( 1The abbreviations used are: MoAbmonoclonal antibodyPGI2prostaglandin I2PTPprotein tyrosine phosphorylationPAGEpolyacrylamide gel electrophoresis.) that induced rapid aggregation were directed against CD9, as presented at the platelet workshop of the IV Leucocyte Typing Conference in Vienna (Powling et al., 1989). Anti-CD9 MoAb is a potent activator of platelet function comparable to thrombin and induces the entire range of functions, including aggregation, granule secretion, protein phosphorylation, phosphoinositide hydrolysis with Ca2+ mobilization, and arachidonic acid metabolism. These findings suggested that CD9 is unique among platelet membrane glycoproteins and that it is a signal transducer. Molecular cloning of CD9 revealed that it is a multiply inserted membrane protein containing four putative transmembrane domains, suggesting that it could indeed be involved in signal transduction pathways (Boucheix et al., 1991) Various attempts have been made to clarify the mechanism by which anti-CD9 MoAbs activate platelets. Phospholipase A2 activation plays an important role but is not a prerequisite (Ozaki et al., 1991). CD9 physically associates with GPIIb/IIIa in the course of anti-CD9 MoAb-induced platelet activation (Slupsky et al., 1989). These studies were based upon the concept that the effects of anti-CD9 MoAbs are exerted through CD9. However, this concept was challenged by recent findings that F(ab′)2 fragments of anti-CD9 MoAbs lack the ability of platelet activation and that the blocking of the FcγII receptor by corresponding monoclonal antibodies inhibited aggregation and Ca2+ mobilization induced by anti-CD9 MoAbs (Slupsky et al., 1989; Worthington et al., 1990). Moreover, stimulation of the FcγII receptor by cross-linkage or by aggregated IgG presented a picture of platelet activation similar to that of MoAbs to CD9 (Henson and Spiegelberg, 1973; Anderson and Anderson, 1990). These findings imply that the signal transduction pathway is mediated entirely through the FcγII receptor, independent of CD9.There is an increasing body of evidence for an important role of protein tyrosine phosphorylation facilitated by tyrosine kinases in the regulation of cell functions, especially those related to cell growth and oncogenesis. While platelets lack the ability to proliferate, they possess a high level of tyrosine kinase activity. All platelet tyrosine kinases reported to date are non-receptor types, p60c-src being the most abundant (Rendu et al., 1989). In addition to p60c-src, several tyrosine kinases including p59fyn, p62yes, p54/58lyn, p72syk, and p125FAK have been identified (Huang et al., 1991; Lipfert et al., 1992). Upon platelet activation induced by various stimulators, a set of proteins undergo tyrosine phosphorylation (Nakamura and Yamamura, 1989; Salari et al., 1990). Although it is not yet clear which tyrosine kinase is responsible for a particular tyrosine-phosphorylated protein, several kinases change their activities upon platelet stimulation. The activity of p72syk is rapidly increased by 10-fold upon thrombin activation, reaching a maximum at 10 s (Taniguchi et al., 1993). Platelet activation also elevates the p60c-src activity, albeit to a lesser degree and with a slower time course (Wong et al., 1992). The activity of p125FAK appears to be modified even later by fibrinogen binding to glycoprotein IIb/IIIa on the platelet membrane (Lipfert et al., 1992). These lines of evidence suggest that protein tyrosine phosphorylation and tyrosine kinases are actively engaged in the regulation of platelet functions from the initial phase of activation to the late stage of aggregation.Recently, we found that anti-CD9 MoAb induces protein tyrosine phosphorylation and that there is an increased level of 3′-phosphorylated polyphosphoinositides, the production of which is physiologically related to tyrosine kinase activity (Yatomi et al., 1993). In this study, we investigated the changes in p72syk activity induced by anti-CD9 MoAb with reference to protein tyrosine phosphorylation.EXPERIMENTAL PROCEDURESMaterials and ChemicalsMoAb against p72syk, p59fyn, or p54/58lyn was obtained from Wako Chemicals (Tokyo). MoAbs against p60c-src(GD11) and phosphotyrosine (4G10) were obtained from Upstate Biotechnology. Acetoxymethyl ester of fura 2 were from Dojin Chemicals (Kumamoto, Japan). GRGDS peptides were obtained from Peptide Institute (Osaka, Japan). EGTA, enolase, prostaglandin I2 (PGI2), leupeptin, phenylmethylsulfonyl fluoride, and sodium orthovanadate were purchased from Sigma. Protein A-Sepharose and CNBr-activated Sepharose were from Pharmacia Japan (Tokyo). Hepes buffer containing 138 mM NaCl, 2.8 mM KCl, 0.8 mM KH2PO4, 0.8 mM MgCl2, 10 mM Hepes (pH 7.2), and 5.5 mM glucose was sterilized by filtration and stored at 4°C until use. NNKY 1-19, anti-CD9 MoAb, was raised by immunizing mice with human platelets (Nagata et al., 1990). Another anti-CD9 MoAb, PMA2, was a generous gift from Dr. Takaaki Hato (Ehime University, Japan) (Hato et al., 1990). F(ab′)2 fragments of NNKY 1-19 or PMA2 were prepared by pepsin digestion (Lamoyi and Nisonoff, 1983). Briefly, NNKY 1-19 was dialyzed overnight at 4°C against 100 mM acetate buffer, pH 7.0. Pepsin (3% w/w) was added, and the mixture was incubated in acetate buffer, pH 4.2, for 12 h at 37°C. The solution was fractionated on a Sephadex G150 column to obtain F(ab′)2 fragments, and the purity of the F(ab′)2 was confirmed by SDS-PAGE.Platelet SeparationCitrated, anti-coagulated venous blood was obtained from healthy human donors who had not received any medication for a minimum of two weeks to the The blood was at for min to obtain were by as and and at a of in Hepes buffer containing mM Ca2+ of and of obtained as fura at a of was added, and the mixture was incubated at for The platelets were and at a of 2 was with a with an s from to and the was set at The were from the of fura 2 at and et al., platelets were with anti-CD9 MoAb or F(ab′)2 fragments with the of the was with an of buffer 100 mM pH mM NaCl, 5 mM 2 mM mM phenylmethylsulfonyl fluoride, and 100 The was and by at for 5 The was with Sepharose and with antibody to protein A-Sepharose or CNBr-activated The mixture was for 2 h at The Sepharose were with The was two was used for and the was for in kinase In kinase was as and 1993). The were with buffer mM NaCl, 5 mM 10 mM pH incubated with of kinase buffer mM pH 10 mM with or without 10 of The was by the addition of 10 of and 2 10 min at the was by the addition of buffer and to for The proteins were by or and The membrane was with for and with a by buffer was to platelets with anti-CD9 MoAb for the and the mixture was for In proteins for immunoprecipitation kinase were Platelet proteins were by and The were incubated with MoAb directed to phosphotyrosine or p60c-src for binding was IgG and with by NNKY 1-19, Anti-CD9 the of mM Ca2+ and without NNKY 1-19 at as as induced platelet aggregation, and (Nagata et al., 1990). The of NNKY 1-19 among but in the range of to 10 In NNKY 1-19 was used at a of 10 Upon NNKY 1-19 a set of tyrosine-phosphorylated proteins with in the time course as as s after stimulation and to after several The appearance of and was a late and to those to be related to aggregation in platelet activation et al., 1990), of did not platelets were with GRGDS not F(ab′)2 fragments of NNKY 1-19 to a of had effects on platelets in of the appearance of aggregation, or that stimulation of FcγII receptors is required for the full picture of platelet activation et al., of Various on by NNKY found that Ca2+ and the production of A2 platelet activation induced by a MoAb to CD9 (Ozaki et al., 1991). the effects of Ca2+ with and of were on NNKY 1-19-induced and in were with mM for min and and in Hepes buffer containing and of Ca2+ and induced by NNKY 1-19 in of 2 The appearance of was but in contrast to the control with Ca2+ and the of persisted for to min not The and were at the of PGI2 on NNKY 1-19-induced PGI2 the intracellular cAMP which induced by thrombin et al., 1990). platelets with PGI2 for 5 min completely the appearance of aggregation, and induced by NNKY 1-19 not 1-19 a in p72syk-associated with of 1-19 stimulation increased the level of p72syk which peaked s after stimulation and subsided to level revealed a which was that for thrombin activation (Taniguchi et al., 1993). The acid of p72syk was tyrosine et al., and not with the change in in kinase assays revealed that the tyrosine kinase activity for was increased transiently with the of a tyrosine-phosphorylated protein MoAb revealed that the was p60c-src suggesting that p60c-src transiently associates with p72syk upon NNKY 1-19-induced platelet MoAb or did not p60c-src, suggesting that p60c-src associates with p72syk platelet activation induced by anti-CD9 MoAb not tyrosine kinase activity induced by anti-CD9 MoAb. in a buffer containing mM Ca2+ were with 10 NNKY 1-19 for the The was with buffer, and was by immunoprecipitation with MoAb. were to MoAb or to in kinase as the from of with induced by anti-CD9 MoAb stimulation. were with NNKY 1-19, and proteins were by immunoprecipitation with MoAb. The was to and was of NNKY 1-19 a in the p72syk-associated and the of with F(ab′)2 of NNKY 1-19 at a of 10 also increased the level of p72syk and the association of tyrosine-phosphorylated protein with p72syk. However, in contrast to an in the p72syk activity and the of the from p72syk, the was to 5 min after stimulation this the level of p72syk and the associated was the maximum level by intact IgG of NNKY 1-19. with revealed the with p72syk not the of F(ab′)2 fragments was not with intact antibody was confirmed by not an receptor MoAb, was used to receptor activation induced by intact The absence of effects of on the increased tyrosine kinase activity induced by F(ab′)2 fragments of that F(ab′)2 fragments of are of p72syk the that F(ab′)2 fragments of anti-CD9 MoAb p72syk activation in platelets, the effects of another CD9 MoAb, PMA2 (Hato et al., 1990), were on the changes in p72syk-associated tyrosine kinase activity and the association p72syk and that the effects of intact IgG PMA2 or the F(ab′)2 fragments of PMA2 were similar to those of NNKY 1-19. transient increase in the level of p72syk and the association p72syk and p60c-src was observed with intact and were with the F(ab′)2 tyrosine kinase activity induced by F(ab′)2 fragments of anti-CD9 MoAb with that by intact in a buffer containing mM Ca2+ were with 10 intact IgG or F(ab′)2 fragments of NNKY 1-19 for the The was with buffer, and was by immunoprecipitation with MoAb. In kinase was on the as intact F(ab′)2 of receptor MoAb, on tyrosine kinase activity induced by anti-CD9 MoAb F(ab′)2 were incubated with 10 for and the changes in tyrosine kinase was assessed at the of F(ab′)2 fragments, 10 of were added, and the changes in tyrosine kinase activity were for another min tyrosine kinase activity and association with induced by intact antibody or F(ab′)2 fragments of PMA2, another anti-CD9 MoAb. in a buffer containing mM Ca2+ were with 10 intact antibody or F(ab′)2 fragments of PMA2, an anti-CD9 MoAb for the The was with buffer, and was by immunoprecipitation with MoAb. were to MoAb or to in kinase as the from and in kinase and MoAb. and the changes induced by intact and the changes induced by F(ab′)2 fragments of of Various on p72syk-associated by NNKY the elevated level of tyrosine kinase activity induced by NNKY 1-19. The tyrosine kinase activity associated with p72syk was at s after stimulation albeit to a lesser degree that at 10 s MoAb that the association of p60c-src with p72syk was also However, the of changes in p72syk-associated tyrosine kinase including a transient increase in and the transient association of p60c-src with p72syk, by a in kinase activity and the of p60c-src, was similar to that of the control without effects of on tyrosine kinase activity and association and induced by anti-CD9 MoAb. was incubated with or without mM for were and in a buffer containing were with 10 NNKY 1-19 for the and the was with was by immunoprecipitation with MoAb. The was by in kinase or to by MoAb. in kinase of with the from aggregation modified the changes in p72syk activation induced by anti-CD9 MoAb. of Ca2+ with 2 mM and GRGDS to platelet aggregation did not p72syk activation in of and the in kinase activity and However, a in the tyrosine kinase activity, which appears min after was not observed in the absence of of GRGDS peptides on and tyrosine kinase activity induced by anti-CD9 MoAb. Ca2+ was with 2 mM EGTA, and GRGDS peptides were to platelet aggregation. were with 10 for the The was with buffer, and was by immunoprecipitation with MoAb. were to MoAb or to in kinase as the from in kinase platelets were incubated with PGI2 for 5 the of changes in the p72syk-associated tyrosine kinase activity was similar to that observed without aggregation. The elevated level of tyrosine kinase activity persisted even at 5 min after activation, and the association of p60c-src with p72syk as assessed by phase of and studies have suggested that the platelet activation induced by anti-CD9 MoAb is upon FcγII receptor stimulation. F(ab′)2 fragments that lack the ability to the FcγII receptor did not or of intracellular granule et al., 1990). induced by anti-CD9 MoAb was inhibited by of the platelets with MoAb (Huang et al., 1992). upon the fact that FcγII receptor as that by the cross-linkage of the is to platelet activation, it been the binding of anti-CD9 MoAb to CD9 on the platelet membrane by any signal that to platelet could to the binding of the of MoAb to the FcγII an anti-CD9 MoAb (Nagata et al., 1990), the findings that the binding of MoAb to CD9 in the absence of FcγII receptor stimulation did not protein tyrosine phosphorylation or platelet aggregation but also that F(ab′)2 fragments of per se intracellular in of p72sykactivation and the association of p60c-src with p72syk. The of intact antibody was by the of receptor MoAb. that the F(ab′)2 fragments of another anti-CD9 MoAb, PMA2 (Hato et al., 1990), are of p72syk the that antibody binding to CD9 a signal(s) leading to p72syk et have that CD9 an activation signal in platelets, based upon their with anti-CD9 MoAb The association CD9 and glycoprotein IIb/IIIa in platelets (Slupsky et al., and that with CD9 and the receptor in et al., that CD9 a function for various cell surface findings a for the signal that CD9 platelets. non-receptor tyrosine kinases have been found to with cell surface et al., 1990; et al., 1991). recent evidence for the association receptor and p72syk et al., 1993). In platelets, p59fyn, p62yes, and p54/58lyn with (Huang et al., 1991). have found that p72syk associates with p60c-src platelet activation induced by CD9 MoAb. to cell types, it is to that CD9 or related membrane protein a signal(s) to p72syk and CD9 tyrosine kinases increase in the p72syk-associated tyrosine kinase activity with association p72syk and p60c-src induced by F(ab′)2 fragments, not to protein tyrosine phosphorylation or of platelet These findings suggest that an signal(s) mediated by FcγII receptor is required for the full picture of platelet PGI2 which elevates the intracellular cAMP completely inhibited the appearance of and aggregation induced by intact IgG of anti-CD9 MoAb, whereas p72syk activation and association p72syk and p60c-src was The in p72syk-associated tyrosine kinase activity and the of p60c-src from p72syk, which min after activation with intact IgG of anti-CD9 MoAb, was by PGI2 PGI2 the of intact IgG anti-CD9 MoAb-induced activation to similar to that with F(ab′)2 findings suggest that cAMP acts at a step distal to the activation of p72syk and association p72syk and p60c-src and that intracellular cAMP facilitated by PGI2 at a particular step of the signal transduction pathway that FcγII receptor activation to and the of p72syk and intact IgG of anti-CD9 MoAb, which induces a full picture of platelet activation, an increase in the p72syk-associated tyrosine kinase activity and association p72syk and p60c-src are s at F(ab′)2 fragments the led to the activation of p72syk and association the two tyrosine These findings suggest that FcγII receptor stimulation induces the p60c-src and the in p72syk-associated tyrosine kinase activity. or the pathway not a role in they to the of or of pathways did not p72syk activation or the association and the and the of p72syk-associated tyrosine kinase activity. the aggregation appears to a role on the p72syk and the in p72syk-associated tyrosine kinase activity. number of kinases including to the in an et al., 1991; and and to the proteins. p72syk also to the upon platelet activation et al., is that the associated of p72syk to the the of p60c-src associated with p72syk, to we are not to that the associated of p72syk and with the not the of aggregation the association p72syk and The of p72syk in MoAb after NNKY 1-19 stimulation was the as that of the state not of p72syk associated with the the of the in p72syk-associated tyrosine kinase activity, we lack The rapid activation of p72syk and s after stimulation been with platelet activation induced by thrombin and A2 (Taniguchi et al., et al., 1993). is that p72syk is the course of NNKY 1-19 activation, which is mediated by FcγII receptor stimulation and upon of p72syk been suggested for receptor with and et al., et al., and for receptor stimulation with a cell et al., 1993). association p72syk and of receptors an important role in signal transduction mediated by receptors et al., platelets, of FcγII receptors or aggregated IgG induces and of platelet activation and Anderson, 1990; et al., et al., 1993). have found that of FcγII receptors induces tyrosine phosphorylation of p72syk and elevates the kinase activity, which that p72syk is also involved in the stimulation of the FcγII However, we have also found that a tyrosine kinase from p72syk with FcγII which not in platelet activation induced by anti-CD9 in we are to that FcγII receptor from anti-CD9 MoAb in the of platelet of FcγII receptors a signal(s) receptor by the of receptors and upon we suggest that platelet activation induced by anti-CD9 MoAb two by the binding of anti-CD9 MoAb to CD9 leading to the activation of p72syk and the association p72syk and p60c-src, and another that is mediated by the FcγII The in of p72syk activation and association p72syk and p60c-src but not to the full picture of platelet The a signal(s) that is by intracellular cAMP and in with CD9 activation it to platelet activation in of and aggregation. the also p72syk activation to be INTRODUCTIONA number of antibodies directed against antigens on the platelet membrane activate platelets (Horsewood et al., 1991). Whereas the antigens involved are diverse, the known antibodies with stimulatory properties are predominantly against CD9, a 24-kDa cell surface glycoprotein (Higashihara et al., 1985; Rendu et al., 1987; Jennings et al., 1990; Carroll et al., 1990), which is confirmed by the fact that most of the monoclonal antibodies (MoAbs)1( 1The abbreviations used are: MoAbmonoclonal antibodyPGI2prostaglandin I2PTPprotein tyrosine phosphorylationPAGEpolyacrylamide gel electrophoresis.) that induced rapid aggregation were directed against CD9, as presented at the platelet workshop of the IV Leucocyte Typing Conference in Vienna (Powling et al., 1989). Anti-CD9 MoAb is a potent activator of platelet function comparable to thrombin and induces the entire range of functions, including aggregation, granule secretion, protein phosphorylation, phosphoinositide hydrolysis with Ca2+ mobilization, and arachidonic acid metabolism. These findings suggested that CD9 is unique among platelet membrane glycoproteins and that it is a signal transducer. Molecular cloning of CD9 revealed that it is a multiply inserted membrane protein containing four putative transmembrane domains, suggesting that it could indeed be involved in signal transduction pathways (Boucheix et al., 1991) Various attempts have been made to clarify the mechanism by which anti-CD9 MoAbs activate platelets. Phospholipase A2 activation plays an important role but is not a prerequisite (Ozaki et al., 1991). CD9 physically associates with GPIIb/IIIa in the course of anti-CD9 MoAb-induced platelet activation (Slupsky et al., 1989). These studies were based upon the concept that the effects of anti-CD9 MoAbs are exerted through CD9. However, this concept was challenged by recent findings that F(ab′)2 fragments of anti-CD9 MoAbs lack the ability of platelet activation and that the blocking of the FcγII receptor by corresponding monoclonal antibodies inhibited aggregation and Ca2+ mobilization induced by anti-CD9 MoAbs (Slupsky et al., 1989; Worthington et al., 1990). Moreover, stimulation of the FcγII receptor by cross-linkage or by aggregated IgG presented a picture of platelet activation similar to that of MoAbs to CD9 (Henson and Spiegelberg, 1973; Anderson and Anderson, 1990). These findings imply that the signal transduction pathway is mediated entirely through the FcγII receptor, independent of CD9.There is an increasing body of evidence for an important role of protein tyrosine phosphorylation facilitated by tyrosine kinases in the regulation of cell functions, especially those related to cell growth and oncogenesis. While platelets lack the ability to proliferate, they possess a high level of tyrosine kinase activity. All platelet tyrosine kinases reported to date are non-receptor types, p60c-src being the most abundant (Rendu et al., 1989). In addition to p60c-src, several tyrosine kinases including p59fyn, p62yes, p54/58lyn, p72syk, and p125FAK have been identified (Huang et al., 1991; Lipfert et al., 1992). Upon platelet activation induced by various stimulators, a set of proteins undergo tyrosine phosphorylation (Nakamura and Yamamura, 1989; Salari et al., 1990). Although it is not yet clear which tyrosine kinase is responsible for a particular tyrosine-phosphorylated protein, several kinases change their activities upon platelet stimulation. The activity of p72syk is rapidly increased by 10-fold upon thrombin activation, reaching a maximum at 10 s (Taniguchi et al., 1993). Platelet activation also elevates the p60c-src activity, albeit to a lesser degree and with a slower time course (Wong et al., 1992). The activity of p125FAK appears to be modified even later by fibrinogen binding to glycoprotein IIb/IIIa on the platelet membrane (Lipfert et al., 1992). These lines of evidence suggest that protein tyrosine phosphorylation and tyrosine kinases are actively engaged in the regulation of platelet functions from the initial phase of activation to the late stage of aggregation.Recently, we found that anti-CD9 MoAb induces protein tyrosine phosphorylation and that there is an increased level of 3′-phosphorylated polyphosphoinositides, the production of which is physiologically related to tyrosine kinase activity (Yatomi et al., 1993). In this study, we investigated the changes in p72syk activity induced by anti-CD9 MoAb with reference to protein tyrosine phosphorylation.
40
Miller Huang, Joseph B. Bolen, J W Barnwell et al. · Proceedings of the National Academy of Sciences · 1991 · 415 citations